Please use this identifier to cite or link to this item:
|Title:||Imaging investigations of the ruthenium(III) anti-cancer drugs, NAMI-A and KP1019, and novel analogues.|
|School/Discipline:||School of Chemistry and Physics|
|Abstract:||The success of platinum-based anti-cancer agents, such as cisplatin, has led to further investigation of the utilisation of other non-platinum metal compounds in cancer therapy. The research has generated particular interest in ruthenium-based chemotherapeutics, as ruthenium species display numerous characteristics which make them appropriate for drug design. Numerous small-molecule ruthenium complexes e.g., NAMI-A (new anti-metastatic inhibitor; ‘A’ stands for first compound in the series; [ImH][trans-RuCl₄(DMSO)(Im)]; Im = imidazole) and KP1019 (Keppler compound 1019; [IndH][trans-RuCl₄Ind₂]; Ind = indazole), have been discovered and found to exhibit promising anticancer properties without complete knowledge about the mechanism of their activity. To develop more targeted drugs with reduced toxicity, it is important to have an accurate knowledge about the mechanism of anti-metastatic activity of these drugs in a complete biological system. Our specific interest in this research has been concerned with the investigation of anti-metastatic activity of analogues of NAMI-A and KP1019 by advanced techniques such as synchrotron-based X-ray fluorescence imaging (XRF) and fluorescent microscopy imaging. A series of ruthenium(III) complexes, which are analogous to either NAMI-A or KP1019, have been synthesised and structurally characterised and their pharmacological activities have been investigated in vitro. The intracellular uptake and distribution of these complexes in human lung cancer cell line (A549) was explored by synchrotron-based X-ray fluorescence microscopy and optical fluorescent microscopy. The intracellular distribution of ruthenium in individual A549 cells treated with KP1019 was revealed by XRF and the results demonstrate an accumulation of ruthenium inside the cytosol and the nucleus. On the contrary, NAMI-A treated cells are devoid of any alteration in intracellular distribution of elements, indicating a membrane-binding mechanism for the cytotoxic activity of NAMI-A. The results in turn demonstrate a different cellular destiny for the complexes, NAMI-A and KP1019. The selective aggregation or intracellular speciation of ruthenium inside the cancer cells, treated with iodine substituted KP1019 analogues, was investigated by synchrotron-based μ-XRF studies. The addition of an iodinated ligand to the parent complex significantly altered the overall distribution of ruthenium across the cell from that observed for the parent complex. The ‘double-tag’ approach, tagging the N-heterocyclic ligand on KP1019 analogues with iodine and then tracking the cellular distribution of both ruthenium and iodine, demonstrated that the Ru-N bond in the treatment compound remained intact inside the cells. A significant increase in the concentration of both ruthenium and iodine inside the nucleus compared to that of control cells proved that the complexes selectively targeted and aggregated inside the nucleus of the treated cells. The distinct cellular pathways of the ruthenium(III) complexes have been investigated by the functionalisation of the imidazole ligand of NAMI-A with other optically fluorescent functionalities. With the aim of eliminating the fluorescence arising from the counter cations, tetramethylammonium analogues were synthesised and characterised. The observed optical properties thus reflected the contribution from the metal complex anion only. The in vitro investigation of the synthesised complexes in lung cancer cells (A549) demonstrated that the functionalisation of NAMI-A does not significantly change the cytotoxic properties of the synthesised analogues. Numerous analogues of NAMI-A with enhanced imaging and targeting functionalities could be synthesised to investigate the biotransformation of ruthenium containing metabolites inside the cancer cell. In general, a number of new biologically active ruthenium(III) complexes, which are analogous to the model complexes NAMI-A and KP1019, have been synthesised and characterised. Their intracellular speciation, aggregation and the optical fluorescent properties have been investigated. The acquired knowledge on the cytotoxicity, intracellular distribution and speciation of treated NAMI-A and KP1019 analogues can contribute to the investigation of the mechanism of anti-metastatic activity of these drugs inside the cancer cells. It may lead to the further development of new ruthenium chemotherapeutics having wide spectrum of activity when compared to platinum-based drugs.|
|Advisor:||Harris, Hugh Hamlyn|
|Dissertation Note:||Thesis (Ph.D.) -- University of Adelaide, School of Chemistry and Physics, 2014|
|Keywords:||fluorescent imaging; ruthenium(III); anti-cancer; NAMI-A; KP1019|
|Provenance:||This electronic version is made publicly available by the University of Adelaide in accordance with its open access policy for student theses. Copyright in this thesis remains with the author. This thesis may incorporate third party material which has been used by the author pursuant to Fair Dealing exceptions. If you are the owner of any included third party copyright material you wish to be removed from this electronic version, please complete the take down form located at: http://www.adelaide.edu.au/legals|
Copyright material removed from digital thesis. See print copy in University of Adelaide Library for full text.
|Appears in Collections:||Research Theses|
Files in This Item:
|01front.pdf||103.68 kB||Adobe PDF||View/Open|
|02whole.pdf||13.32 MB||Adobe PDF||View/Open|
|Permissions||Library staff access only||726.69 kB||Adobe PDF||View/Open|
|Restricted||Library staff access only||52.22 MB||Adobe PDF||View/Open|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.